

Cambridge University Press

978-1-107-48403-0 - Handbook of Drugs in Intensive Care: An A-Z Guide:

Fifth Edition

Henry G W Paw

Frontmatter

[More information](#)

Handbook of Drugs in Intensive Care

Fifth Edition

Cambridge University Press

978-1-107-48403-0 - Handbook of Drugs in Intensive Care: An A-Z Guide:

Fifth Edition

Henry G W Paw

Frontmatter

[More information](#)

This book is dedicated to Georgina Paw.

Cambridge University Press

978-1-107-48403-0 - Handbook of Drugs in Intensive Care: An A-Z Guide:

Fifth Edition

Henry G W Paw

Frontmatter

[More information](#)

Handbook of
Drugs in Intensive Care
An A-Z Guide
Fifth Edition

Henry G W Paw

BPharm MRPharmS MBBS FRCA FFICM

Consultant in Intensive Care Medicine and Anaesthesia

York Hospital

York

UK

Rob Shulman

BSc(Pharm) MRPharmS DipClinPharm DHC(Pharm)

Lead Pharmacist in Critical Care

Honorary Associate Professor in Clinical Pharmacy Practice

UCL School of Pharmacy

Honorary Lecturer, Department of Medicine, UCL

University College London Hospitals

London

UK



CAMBRIDGE
UNIVERSITY PRESS

Cambridge University Press
978-1-107-48403-0 - Handbook of Drugs in Intensive Care: An A-Z Guide:
Fifth Edition
Henry G W Paw
Frontmatter
[More information](#)

CAMBRIDGE UNIVERSITY PRESS

University Printing House, Cambridge CB2 8BS, United Kingdom

Published in the United States of America by Cambridge University Press, New York

Cambridge University Press is part of the University of Cambridge.

It furthers the University's mission by disseminating knowledge in the pursuit of education, learning and research at the highest international levels of excellence.

www.cambridge.org

Information on this title: www.cambridge.org/9781107484030

© Henry Paw and Rob Shulman 2013

This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2000

Second Edition 2002

Third Edition 2006

Fourth Edition 2009

Fifth Edition 2013

Reprinted with corrections 2014

Printed in the United Kingdom by CPI Group Ltd, Croydon CR0 4YY

A catalogue record for this publication is available from the British Library

Library of Congress Cataloguing in Publication data

ISBN 978-1-107-48403-0 paperback

Cambridge University Press has no responsibility for the persistence or accuracy of URLs for external or third-party internet websites referred to in this publication, and does not guarantee that any content on such websites is, or will remain, accurate or appropriate.

Every effort has been made in preparing this publication to provide accurate and up-to-date information which is in accord with accepted standards and practice at the time of publication. Although case histories are drawn from actual cases, every effort has been made to disguise the identities of the individuals involved. Nevertheless, the authors, editors and publishers can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors and publishers therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this publication. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use.

Cambridge University Press

978-1-107-48403-0 - Handbook of Drugs in Intensive Care: An A-Z Guide:

Fifth Edition

Henry G W Paw

Frontmatter

[More information](#)**CONTENTS**

Introduction	vii
How to use this book	viii
Abbreviations	x
Acknowledgements	xiii

DRUGS: AN A-Z GUIDE 1**SHORT NOTES** 243

Routes of administration	245
Loading dose	247
Drug metabolism	247
Enzyme systems	248
Drug excretion	248
Drug tolerance	249
Drug interactions	249
Therapeutic drug monitoring	250
Target range of concentration	251
Pharmacology in the critically ill	252
Cardiopulmonary resuscitation	254
Drugs in advanced life support	257
Management of acute major anaphylaxis	259
Management of severe hyperkalaemia	260
Management of malignant hyperthermia	261
Sedation, analgesia and neuromuscular blockade	263
A practical approach to sedation and analgesia	266
Opioid Conversion table	267
Management of status epilepticus	270
Prevention of delirium tremens and alcohol withdrawal syndrome	274
Prevention of Wernicke–Korsakoff syndrome	275
Anti-arrhythmic drugs	276
Inotropes and vasopressors	277
Bronchospasm	284
Anti-ulcer drugs	285
Immunonutrition in the ICU	285
Corticosteroids	286
Short synacthen test	287
Bone marrow rescue following nitrous oxide	287
Antioxidants	288
Post-splenectomy prophylaxis	289
Anti-microbial drugs	292
Bacterial gram staining	297
Antibiotics: sensitivities	298
Renal replacement therapy	300
Extracorporeal drug clearance: basic principles	304

Cambridge University Press

978-1-107-48403-0 - Handbook of Drugs in Intensive Care: An A-Z Guide:

Fifth Edition

Henry G W Paw

Frontmatter

[More information](#)

Drug doses in renal failure/renal replacement therapy	305
Chemical pleurodesis of malignant pleural effusion	318

APPENDICES 321

Appendix A: Creatinine clearance	323
Appendix B: Weight conversion (stones/lb to kg)	324
Appendix C: Body mass index (BMI) calculator	325
Appendix D: Lean body weight charts	326
Appendix E: Infusion rate/dose calculation	328
Appendix F: Drug compatibility chart	329
Appendix G: Omeprazole administration record	330
Appendix H: Sodium content of oral medications	332
Appendix I: Drug management of the brain-stem-dead donor	334
Appendix J: Vancomycin by continuous infusion	335
Appendix K: Child-Pugh score	337
Appendix L: Severe sepsis algorithm	338

DRUG INDEX 339

Inside back cover: IV compatibility chart

Cambridge University Press

978-1-107-48403-0 - Handbook of Drugs in Intensive Care: An A-Z Guide:

Fifth Edition

Henry G W Paw

Frontmatter

[More information](#)

INTRODUCTION

Since the publication of the fourth edition in 2010, there have been several new drugs introduced to the critical care setting. This book has now been extensively updated. The main purpose of this book is to provide a practical guide that explains how to use drugs safely and effectively in a critical care setting. Doctors, nurses, pharmacists and other healthcare professionals caring for the critically ill patient will find it useful. It is not intended to list every conceivable complication and problem that can occur with a drug but to concentrate on those the clinician is likely to encounter. The book should be seen as complementary to, rather than replacing, the standard textbooks.

The book is composed of two main sections. The A-Z guide is the major part and is arranged alphabetically by the non-proprietary name of the drug. This format has made it easier for the user to find a particular drug when in a hurry. The discussion on an individual drug is restricted to its use in the critically ill adult patient. The second part is comprised of short notes on relevant intensive care topics. Inside the back cover is a colour fold-out chart showing drug compatibility for intravenous administration.

I am very fortunate to have on board a senior ICU pharmacist for this edition. While every effort has been made to check drug dosages based on a 70 kg adult and information about every drug, it is still possible that errors may have crept in. I would therefore ask readers to check the information if it seems incorrect. In addition, I would be pleased to hear from any readers with suggestions about how this book can be improved. Comments should be sent via e-mail to: henry.paw@york.nhs.uk.

HGWP
York 2013

Cambridge University Press

978-1-107-48403-0 - Handbook of Drugs in Intensive Care: An A-Z Guide:

Fifth Edition

Henry G W Paw

Frontmatter

[More information](#)

HOW TO USE THIS BOOK

European law (directive 92/27/EEC) requires the use of the Recommended International Non-proprietary Name (rINN) in place of the British Approved Name (BAN). For a small number of drugs these names are different. The Department of Health requires the use of BAN to cease and be replaced by rINN with the exceptions of adrenaline and noradrenaline. For these two drugs both their BAN and rINN will continue to be used.

The format of this book was chosen to make it more 'user friendly' – allowing the information to be readily available to the reader in times of need. For each drug there is a brief introduction, followed by the following categories:

Uses

This is the indication for the drug's use in the critically ill. There will be some unlicensed use included and this will be indicated in brackets.

Contraindications

This includes conditions or circumstances in which the drug should not be used – the contraindications. For every drug, this includes known hypersensitivity to the particular drug or its constituents.

Administration

This includes the route and dosage for a 70 kg adult. For obese patients, estimated ideal body weight should be used in the calculation of the dosage (Appendix D). It also advises on dilutions and situations where dosage may have to be modified. To make up a dilution, the instruction 'made up to 50 ml with 0.9% sodium chloride' means that the final volume is 50 ml. In contrast, the instruction 'to dilute with 50 ml 0.9% sodium chloride' could result in a total volume >50 ml. It is recommended that no drug should be stored for >24 h after reconstitution or dilution.

How not to use ...

Describes administration techniques or solutions for dilution which are not recommended.

Adverse effects

These are effects other than those desired.

Cautions

Warns of situations when the use of the drug is not contraindicated but needs to be carefully watched. This will include key drug-drug interactions.

Cambridge University Press

978-1-107-48403-0 - Handbook of Drugs in Intensive Care: An A-Z Guide:

Fifth Edition

Henry G W Paw

Frontmatter

[More information](#)

Organ failure

Highlights any specific problems that may occur when using the drug in a particular organ failure.

Renal replacement therapy

Provides guidance on the effects of haemofiltration/dialysis on the handling of the drug. For some drugs, data are either limited or not available.

ABBREVIATIONS

ACE-I	angiotensin converting enzyme inhibitor
ACh	acetylcholine
ACT	activated clotting time
ADH	antidiuretic hormone
AF	atrial fibrillation
APTT	activated partial thromboplastin time
ARDS	acute respiratory distress syndrome
AUC	area under the curve
AV	atrioventricular
BP	blood pressure
CABG	coronary artery bypass graft
cAMP	cyclic AMP
CC	creatinine clearance
CMV	cytomegalovirus
CNS	central nervous system
CO	cardiac output
COPD	chronic obstructive pulmonary disease
CPR	cardiopulmonary resuscitation
CSF	cerebrospinal fluid
CT	computerised tomography
CVVH	continuous veno-venous haemofiltration
CVVHD	continuous veno-venous haemodiafiltration
DI	diabetes insipidus
DIC	disseminated intravascular coagulation
DVT	deep vein thrombosis
EBV	Epstein Barr virus
ECG	electrocardiogram
EEG	electroencephalogram
EMD	electromechanical dissociation
ESBL	extended-spectrum beta-lactamases
ETCO ₂	end-tidal carbon dioxide concentration
FBC	full blood count
FFP	fresh frozen plasma
g	gram
GFR	glomerular filtration rate
GI	gastrointestinal
HD	haemodialysis
HOCM	hypertrophic obstructive cardiomyopathy
h	hour
HR	heart rate
ICP	intracranial pressure
ICU	intensive care unit
IHD	ischaemic heart disease
IM	intramuscular
INR	international normalised ratio
IOP	intraocular pressure

IPPV	intermittent positive pressure ventilation
IV	intravenous
K ⁺	potassium
kg	kilogram
l	litre
LFT	liver function tests
LMWH	low molecular weight heparin
MAOI	monoamine oxidase inhibitor
M6G	morphine-6-glucuronide
mg	milligram
MH	malignant hyperthermia
MI	myocardial infarction
MIC	minimum inhibitory concentration
min	minute
ml	millilitre
MRSA	meticillin-resistant <i>Staphylococcus aureus</i>
NG	nasogastric route
ng	nanogram
NIV	non-invasive ventilation
NJ	nasojejunal
nocte	at night
NSAID	non-steroidal anti-inflammatory drugs
PaCO ₂	partial pressure of carbon dioxide in arterial blood
PaO ₂	partial pressure of oxygen in arterial blood
PCA	patient controlled analgesia
PCP	<i>Pneumocystis carinii</i> pneumonia
PCWP	pulmonary capillary wedge pressure
PD	peritoneal dialysis
PE	pulmonary embolism
PEA	pulseless electrical activity
PEG	percutaneous endoscopic gastrostomy
PEJ	percutaneous endoscopic jejunostomy
PO	<i>per orum</i> (by mouth)
PPI	proton pump inhibitor
PR	<i>per rectum</i> (rectal route)
PRN	<i>pro re nata</i> (as required)
PT	prothrombin time
PVC	polyvinyl chloride
PVD	peripheral vascular disease
s	second
SC	subcutaneous
SIRS	systemic inflammatory response syndrome
SL	sublingual
SSRI	selective serotonin re-uptake inhibitors
STEMI	ST-segment elevation myocardial infarction
SVR	systemic vascular resistance
SVT	supraventricular tachycardia

Cambridge University Press
978-1-107-48403-0 - Handbook of Drugs in Intensive Care: An A-Z Guide:
Fifth Edition
Henry G W Paw
Frontmatter
[More information](#)

ABBREVIATIONS

TFT	thyroid function tests
TNF	tumour necrosis factor
TPN	total parenteral nutrition
U&E	urea and electrolytes
VF	ventricular fibrillation
VRE	vancomycin-resistant <i>Enterococcus faecium</i>
VT	ventricular tachycardia
WFI	water for injection
WPW syndrome	Wolff-Parkinson-White syndrome

Cambridge University Press

978-1-107-48403-0 - Handbook of Drugs in Intensive Care: An A-Z Guide:

Fifth Edition

Henry G W Paw

Frontmatter

[More information](#)

ACKNOWLEDGEMENTS

I would like to thank the colleagues from whom I have sought advice during the preparation of this book. In particular, I acknowledge the assistance of Dr Daniel Weiland, Specialty Registrar in Microbiology, and Emily Waterman, Directorate Pharmacist for Critical Care. HP.

I would like to thank the staff of UCLH ICU for asking many searching questions about drug therapy, the answers to many of which fill these pages.

I would also like to acknowledge Keny Mole's UCLH Injectable Medicines Administration Guide.

RS.